Clinical trial
Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate…
NCT00223171 · Université de Sherbrooke, Other · Active, not recruiting
Key facts
| NCT number | NCT00223171 |
|---|---|
| Title | Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers |
| Official title | Randomized, Multicentre, Phase III Study: Assessment of the Duration of Androgen Blockade Combined With Pelvic Irradiation in High-risk Prostate Cancers |
| Acronym | PCS IV |
| Lead sponsor | Université de Sherbrooke, Other |
| Collaborators | AstraZeneca Industry |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Androgen blockade + radiation therapy |
| Enrollment | 630 |
| Start date | Oct 1, 2000 |
| Primary completion | Dec 31, 2026 |
| Completion | Dec 31, 2027 |
| First posted | Sep 22, 2005 |
| Last update posted | Jan 27, 2025 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: